Table 1. Demographics and baseline ocular and disease characteristics.
| Parameters | Effectiveness Analysis (EA) population (N = 617) |
|---|---|
| Mean (SD) age, years | 75.5 (8.7) |
| Gender, Female, n (%) | 335 (54.29) |
| Race, Caucasian, n (%) | 612 (99.19) |
| Time from diagnosis to treatment (days) | |
| n (%) | 584 (94.65) |
| Median | 16 |
| Q1, Q3 | 7; 33 |
| VA, ETDRS letters | |
| Mean (SD) | 53.43 (22.8) |
| Median (Q1; Q3) | 60 (35–70) |
| MNV types (treated eye), n (%) | |
| Classic (type II) | 167 (27.07) |
| Mixed | 52 (8.43) |
| ND | 109 (17.67) |
| Occult (type I) | 218 (35.33) |
| PCV | 27 (4.38) |
| RAP | 44 (7.13) |
| CSRT (μm) | |
| n (%) | 396 (64.18) |
| Mean (SD) | 395.7 (143.1) |
| Median (Q1;Q3) | 369.5 (300.0;463.0) |
| OCT variables | |
| n (%) | 481 (100) |
| Presence of fluid (investigators’ judgment) | 436 (90.64) |
| Intra-retinal fluid | 289 (60.08) |
| Sub-retinal fluid | 314 (65.28) |
| RPE detachment | 285 (59.25) |
| Atrophy | 56 (11.64) |
| Fibrosis | 73 (15.18) |
| Ocular disease history | |
| n(%) | 247 (40.03) |
| Cataract | 38 (6.15) |
| Cataract surgery | 0 (0) |
| Vitrectomy | 0 (0) |
| RPE tear | 0 (0) |
| Other | 43 (6.96) |
OE population: All enrolled patients who had at least one anti-VEGF injection; EA set: All patients in the OE who had a baseline and at least one post-baseline assessment of VA.
CSRT, central sub-field retinal thickness; EA, effectiveness analysis; ETDRS, early treatment diabetic retinopathy study; LP, loading phase; MNV, macular neovascularization; N, total number of patients; n, number of patients; ND, not determined; OE, overall exposed; PCV; polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; RPE, retinal pigment epithelium; SD, standard deviation; VA, visual acuity; VEGF, vascular endothelial growth factor.